Tech Portal Monaco
SEE OTHER BRANDS

Reporting on science and technology news in Monaco

Tech Portal Monaco: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Portal Monaco.

Press releases published on May 27, 2025

Varonis at Infosecurity Europe 2025: Automating Data Security for the AI Era

Varonis at Infosecurity Europe 2025: Automating Data Security for the AI Era

MIAMI and LONDON, May 27, 2025 (GLOBE NEWSWIRE) -- Varonis Systems, Inc. (Nasdaq: VRNS), the leader in data security, announced its full event schedule for Infosecurity Europe 2025, taking place June 3 – 5 at ExCeL London. Varonis proudly returns to …

AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders

AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders

Research Triangle Park, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- AB-1005 was well tolerated with no attributed serious adverse events in participants with mild or moderate Parkinson’s disease (PD) through 18 months post-gene transfer Non-motor assessments …

HashFly Implements Advanced AI For Cloud Mining Operations

HashFly Implements Advanced AI For Cloud Mining Operations

New York City, NY, May 27, 2025 (GLOBE NEWSWIRE) -- HashFly, one of the leading cloud mining platform, is heading into the future with the integration of advanced artificial intelligence (AI) technology into its mining processes. With the use of AI, …

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), …

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK)  No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “ …

TopFX Celebrates 15 Years of Growth in Trading and Liquidity Services

TopFX Celebrates 15 Years of Growth in Trading and Liquidity Services

Mahé, Seychelles, May 27, 2025 (GLOBE NEWSWIRE) -- TopFX is proud to mark its 15th anniversary, celebrating a significant milestone in its journey of providing world-class forex trading solutions, deep liquidity access, and innovative trading technology to …

ZenaTech Provides Quantum Computing Update on ‘Clear Sky' Weather Forecasting Project─AI Drone Swarms to Combat Steep Rise in Billion Dollar Extreme Weather Events

ZenaTech Provides Quantum Computing Update on ‘Clear Sky' Weather Forecasting Project─AI Drone Swarms to Combat Steep Rise in Billion Dollar Extreme Weather Events

VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and …

Breaking News: Rasool Rezvani (RZ) Named Among the Most Influential Crypto Figures of 2025

Breaking News: Rasool Rezvani (RZ) Named Among the Most Influential Crypto Figures of 2025

Dubai, UAE, May 27, 2025 (GLOBE NEWSWIRE) -- In a major recognition of global impact and innovation, Rasool Rezvani—widely known as RZ—has been officially named one of the Top Crypto Entrepreneurs of 2025, according to a recent report by International …

GridCARE Launches with a Mission to Eliminate AI’s Biggest Bottleneck: Immediate Access to Power

GridCARE Launches with a Mission to Eliminate AI’s Biggest Bottleneck: Immediate Access to Power

REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- GridCARE, a new company powering the AI revolution, emerged from stealth today. The company has closed a highly oversubscribed $13.5 million Seed financing round led by Xora, a deep technology venture …

Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the …

Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer

Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on Saturday, May …

Theriva™ Biologics anuncia la presentación de los datos del ensayo clínico de Fase 1 del VCN-01 para el retinoblastoma en ASCO 2025 y la reunión de investigadores para revisar los datos preliminares del ensayo VIRAGE de Fase 2b del VCN-01 para el…

Theriva™ Biologics anuncia la presentación de los datos del ensayo clínico de Fase 1 del VCN-01 para el retinoblastoma en ASCO 2025 y la reunión de investigadores para revisar los datos preliminares del ensayo VIRAGE de Fase 2b del VCN-01 para el…

- Los resultados clínicos y de seguridad del estudio de Fase 1 del VCN-01 (zabilugene almadenorepvec) en pacientes con retinoblastoma refractario se presentarán en una sesión de pósteres en la reunión anual de la Sociedad Americana de Oncología Clínica ( …

Zscaler to Host Innovations Briefing for Investors at Zenith Live 2025

Zscaler to Host Innovations Briefing for Investors at Zenith Live 2025

SAN JOSE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today announced that the company will host an innovations briefing for investors on June 3, 2025. The briefing will take place in Las Vegas, Nevada …

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China

Junshi Biosciences Announces Ongericimab’s sNDA Approval in China

SHANGHAI, May 27, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel …

LIS Technologies Inc. Appoints Leading Regulatory Expert Julie Olivier as its Regulatory Affairs and Licensing Director

LIS Technologies Inc. Appoints Leading Regulatory Expert Julie Olivier as its Regulatory Affairs and Licensing Director

Oak Ridge, Tennessee, May 27, 2025 (GLOBE NEWSWIRE) -- LIS Technologies Inc. (“LIST” or “the Company”), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, today announced that it has …

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and …

NETCLASS TECHNOLOGY INC. and East China Normal University Sign Cooperation Agreement to Pioneer a New Era of Smart Education

NETCLASS TECHNOLOGY INC. and East China Normal University Sign Cooperation Agreement to Pioneer a New Era of Smart Education

SHANGHAI and HONG KONG, May 27, 2025 (GLOBE NEWSWIRE) -- NETCLASS Technology INC. (Nasdaq: NTCL; the “Company” or “NetClass”), a leading B2B smart education IT solutions provider with offices in Shanghai, Hong Kong, Singapore and Tokyo, has officially …

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 …

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U.S. FDA) …

BioCryst to Present at Upcoming Investor Conferences

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: Jefferies Global Healthcare Conference in New York on Wednesday, …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service